Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis

被引：0
|
作者：
Fox, E. [1 ]
Lovett-Racke, A. [2 ]
Inglese, M. [3 ]
Wray, S. [4 ]
Racke, M. [5 ]
Shubin, R. [6 ]
Eubanks, J. [7 ]
Su, W. [7 ]
机构：
[1] Cent Texas Neurol Consultants, Round Rock, TX USA
[2] Ohio State Univ, Microbial Infect & Immun, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, Neurol & Radiol, New York, NY 10029 USA
[4] Hope Neurol, Knoxville, TN USA
[5] Ohio State Univ, Neurol, Columbus, OH 43210 USA
[6] Arcadia Neurol Ctr, Pasadena, CA USA
[7] TG Therapeut, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P793
引用
收藏
页码：407 / 407
页数：1
相关论文
共 50 条
  • [1] Final results of a placebo controlled, Phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS).
    Fox, E.
    Lovett-Racke, A.
    Gormley, M.
    Liu, Y.
    Wray, S.
    Shubin, R.
    Petracca, M.
    Inglese, M.
    Power, S.
    Bosco, J.
    Mok, K.
    Weiss, M.
    Eubanks, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 87 - 87
  • [2] Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets
    Lovett-Racke, A.
    Liu, Y.
    Gormley, M.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 609 - 610
  • [3] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
    Fox, Edward
    Lovett-Racke, Amy E.
    Gormley, Matthew
    Liu, Yue
    Petracca, Maria
    Cocozza, Sirio
    Shubin, Richard
    Wray, Sibyl
    Weiss, Michael S.
    Bosco, Jenna A.
    Power, Sean A.
    Mok, Koby
    Inglese, Matilde
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
  • [4] Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
    Fox, Edward
    Wray, Sibyl
    Shubin, Richard
    Bosco, Jenna
    Weiss, Michael
    Power, Sean
    Mok, Koby
    Eubanks, James
    NEUROLOGY, 2019, 92 (15)
  • [5] Open Label Extension (OLE) of Phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with Relapsing forms of Multiple Sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Mok, K.
    Power, S.
    Bosco, J.
    Weiss, M.
    Eubanks, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 105 - 105
  • [6] 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
    Fox, Edward J.
    Lovett-Racke, Amy
    Wray, Sibyl
    Racke, Michael K.
    Shubin, Richard
    Twyman, Cary
    Eubanks, James
    Su, Wendy
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 23 - 23
  • [7] Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
    Lovett-Racke, Amy
    Liu, Yue
    Racke, Michael
    Shubin, Richard
    Wray, Sibyl
    Su, Wendy
    Eubanks, James
    Fox, Edward
    NEUROLOGY, 2017, 88
  • [8] Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)
    Lovett-Racke, A.
    Liu, Y.
    Racke, M.
    Wray, S.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 511 - 511
  • [9] Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease
    Inglese, M.
    Petracca, M.
    Cocozza, S.
    Wray, S.
    Racke, M.
    Shubin, R.
    Su, W.
    Eubanks, J.
    Fox, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 410 - 411
  • [10] Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)
    Fox, E.
    Wray, S.
    Shubin, R.
    Lovett-Racke, A.
    Huang, D.
    Bass, A.
    Weiss, M.
    Power, S.
    Bosco, J.
    Mok, K.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 543 - 544
12345